News

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Ele­vidys, or a similar ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...
Stocks traded mixed Friday as investors focused on corporate earnings, a day after the S&P 500 and Nasdaq Composite set ...